Royal Bank Of Canada Nuvectis Pharma, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$6.69 - $11.0 $1,806 - $2,970	270 New	270 $2,000
Q1 2024 May 15, 2024	SELL	$6.69 - $11.0 $13,895 - $22,847	-2,077 Reduced 88.5%	270 $2,000
Q4 2023 Feb 14, 2024	BUY	$7.85 - $11.78 $9,883 - $14,831	1,259 Added 115.72%	2,347 $19,000
Q3 2023 Nov 14, 2023	SELL	$12.89 - $16.29 $20,675 - $26,129	-1,604 Reduced 59.58%	1,088 $14,000
Q2 2023 Aug 14, 2023	BUY	$12.62 - $18.4 $33,973 - $49,532	2,692 New	2,692 $42,000
Q3 2022 Nov 14, 2022	BUY	$7.09 - $13.0 $538 - $988	76 New	76 $1,000

1.65M

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $83.9M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.